TP53 and ovarian carcinoma: In addition, we tested the model on one ovarian cancer control cell line and 6 184-hTERT cell lines engineered to induce genomic instability from a diploid background with CRISPR loss of function of TP53 combined with BRCA1 or BRCA2. Both integrated and total CN TreeAlign were run on matched DLP+ and 10x scRNA-seq data (Figs. S24–S53).